EyeCRO are Experts in preclinical efficacy studies in ophthalmic retinopathy, pharmacokinetics, both in vivo and in vitro for clinical and precise formulation services and trial batteries. EyeCRO is a preclinical ophthalmic research organization focused on studies in retina preclinical efficacy, oxygen-induced retinopathy, and ophthalmic pharmacokinetics for clinical and precise formulation services and trial batteries. EyeCRO is a preclinical ophthalmic research organization focused on studies in Laser CNV, Retina preclinical efficacy, and Ophthalmic toxicology for clinical and precise formulation services.

Web developed by Josh Bolinger website design

Ophthalmic Contract Research

EyeCRO is a preclinical ophthalmic research organization focused on retinal disease models, both in vivo and in vitro.  Currently EyeCRO offers models in the areas of ocular angiogenesis, retinal degeneration, retinal vascular permeability, safety and pharmacokinetics. In addition EyeCRO is adding new models every year. EyeCRO also offers its clients formulation services such as developing eye drop formulations,
[Read More...]

About Us

EyeCRO is composed on an internationally recognized team of research scientists specializing in ophthalmic disease. The company was founded in 2005 with a contract to study the effects of one of the world’s largest pharmaceutical company’s drugs in an animal model. EyeCRO started as a way to help support the drug pipeline of a small [...]

Formulation and Bioanalytical

EyeCRO understands that not all test articles are freely integrate able or readily bioavailable. By utilizing a combination of our formulation proficiency and historical awareness of vehicle suitability, we ensure an informed lead candidate selection process and a formulation suitable for your preclinical needs.Successful formulation development needs knowledge of the physicochemical characteristics of the drug. Therefore, we use preformulation screens prior to formal formulation development … [Read More...]

Diabetic Retinopathy, Microalbuminuria Predict GFR Decline

Having diabetic retinopathy and/or microalbuminuria predicted a much higher rate of annual decline … [Read More...]

EyeCRO COO Gives Talk at ARVO

"Dr. Rafal Farjo, Chief Operating Officer of EyeCRO, gives a seminar to Members-in-Training on … [Read More...]

More News

In-Vivo

EyeCRO offers various in vivo studies to better help your organization understand your therapeutic. EyeCRO also has extensive experience in various routes of administration and can customize studies depending on your needs. One of the main advantages in working with EyeCRO is our ability to be flexible.
 
[Read More...]